NASDAQ:IDRA Idera Pharmaceuticals (IDRA) Stock Price, News & Analysis → They said crypto was dead. It went up 100X. (From InvestorPlace) (Ad) Free IDRA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.17▼$7.2352-Week Range N/AVolume21,870 shsAverage Volume464,030 shsMarket Capitalization$450.52 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Idera Pharmaceuticals alerts: Email Address Ad The Bull ReportThe AI Bottleneck No One is Talking AboutRenewable energy is growing at an impressive speed - but not fast enough. This could be one of the greatest periods for the nuclear industry ever.Click here to see who's preparing to meet these needs About Idera Pharmaceuticals Stock (NASDAQ:IDRA)Aceragen, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.Read More Ad Porter & CompanyUrgent new message from Porter StansberryI’ve been in the financial markets for close to three decades… Yet, I’ve never seen an opportunity that’s so urgent, so critical, and yet so overlooked than what is unfolding right now. You see, in one corner of the markets a financial anomaly has emerged that promises to be the single most important story of 2024.Click here now to get what could be the most urgent, and most lucrative research, my team has ever r IDRA Stock News HeadlinesNovember 15, 2023 | forbes.comKiniksa PharmaceuticalsAugust 9, 2023 | investing.comNabriva Therapeutics AG (NBRVF)March 19, 2024 | Porter & Company (Ad)Urgent new message from Porter StansberryI’ve been in the financial markets for close to three decades… Yet, I’ve never seen an opportunity that’s so urgent, so critical, and yet so overlooked than what is unfolding right now. You see, in one corner of the markets a financial anomaly has emerged that promises to be the single most important story of 2024.April 26, 2023 | npr.orgMarginaliaMarch 17, 2023 | washingtonpost.comA mysterious rift propels the story in ‘Take What You Need’January 18, 2023 | finanznachrichten.deIdera Pharmaceuticals, Inc.: Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic OutlookJanuary 17, 2023 | finance.yahoo.comIdera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic OutlookJanuary 10, 2023 | msn.comWhy Bed Bath & Beyond Shares Are Trading Higher By 17%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionMarch 19, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.January 4, 2023 | thestreet.comIdera (IDRA) Stock Soars on GlaxoSmithKline PartnershipNovember 18, 2022 | finanznachrichten.deIdera Pharmaceuticals, Inc.: Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNovember 14, 2022 | finance.yahoo.comIdera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateSeptember 29, 2022 | finance.yahoo.comIdera Pharma Acquires Rare Disease Player, Names New CEOSeptember 28, 2022 | marketwatch.comIdera Pharma Shares Rise Nearly 18% After Aceragen AcquisitionSeptember 28, 2022 | finance.yahoo.comIdera Pharmaceuticals Acquires AceragenSeptember 27, 2022 | benzinga.comIdera Pharmaceuticals Stock (NASDAQ:IDRA), DividendsAugust 9, 2022 | finance.yahoo.comIdera Pharmaceuticals Reports Second Quarter 2022 Financial ResultsMay 17, 2022 | seekingalpha.comIdera halts melanoma trial for cancer candidate after early positive resultsMay 17, 2022 | finance.yahoo.comWhy Are Idera Pharmaceuticals Shares Soaring TodayMay 17, 2022 | finance.yahoo.comIdera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMCMay 5, 2022 | finance.yahoo.comIdera Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate UpdateMarch 31, 2022 | finance.yahoo.comIdera Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdateDecember 15, 2021 | msn.comIdera Shares Fall After Early Tilsotolimod Data, Seeks Collaborating Partners For TLR9 AgonistDecember 14, 2021 | finance.yahoo.comIdera Pharmaceuticals Announces Tilsotolimod UpdatesDecember 8, 2021 | chron.com5 Penny Stocks To Buy According To Analysts & Targets Up To 341%November 8, 2021 | finance.yahoo.comIdera Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateAugust 9, 2021 | finance.yahoo.comIdera Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate UpdateSee More Headlines Receive IDRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Idera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2021Today3/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:IDRA CUSIPN/A CIK861838 Webwww.iderapharma.com Phone(484) 348-1600Fax617-679-5592Employees32Year Founded1989Profitability EPS (Most Recent Fiscal Year)($0.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$98.09 million Net MarginsN/A Pretax MarginN/A Return on Equity-68.74% Return on Assets-34.26% Debt Debt-to-Equity RatioN/A Current Ratio1.56 Quick Ratio1.56 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash Flow0.29 Book Value$0.56 per share Price / BookN/AMiscellaneous Outstanding Shares62,355,000Free Float59,206,000Market Cap$450.52 million OptionableOptionable Beta1.25 Social Links These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. John J. Kirby CPA (Age 50)Chief Financial Officer Comp: $477.41kMr. Bryant David Lim (Age 51)Chief Bus. Officer & Gen. Counsel Comp: $480.96kMr. John C. Taylor (Age 52)CEO & Director Mr. Daniel Salain (Age 55)Chief Operating Officer Mr. Andy Jordan (Age 75)Chief Strategy Officer Dr. Carl Kraus M.D. (Age 53)Chief Medical Officer Dr. Shah Rahimian M.D.Ph.D., Medical Director & Global Clinical Lead for OncologyDr. Joanna Caroline Horobin Ch.B (Age 67)M.B., Advisor Dr. Sudhir Agrawal D.Phil. (Age 68)F.R.S.C., Scientific Advisor Mr. Louis J. Arcudi III (Age 61)M.B.A., MBA, Adviser More ExecutivesKey CompetitorsCaribou BiosciencesNASDAQ:CRBUMetagenomiNASDAQ:MGXAnavex Life SciencesNASDAQ:AVXLTaysha Gene TherapiesNASDAQ:TSHALexeo TherapeuticsNASDAQ:LXEOView All Competitors IDRA Stock Analysis - Frequently Asked Questions How were Idera Pharmaceuticals' earnings last quarter? Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) issued its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.01. When did Idera Pharmaceuticals' stock split? Idera Pharmaceuticals shares split on Friday, November 25th 2022. The 2-1 split was announced on Friday, November 25th 2022. The newly created shares were distributed to shareholders after the closing bell on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. What is Vincent Milano's approval rating as Idera Pharmaceuticals' CEO? 7 employees have rated Idera Pharmaceuticals Chief Executive Officer Vincent Milano on Glassdoor.com. Vincent Milano has an approval rating of 88% among the company's employees. What other stocks do shareholders of Idera Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Idera Pharmaceuticals investors own include Oasis Petroleum (OAS), BioCryst Pharmaceuticals (BCRX), Sorrento Therapeutics (SRNE), Novavax (NVAX), Dynavax Technologies (DVAX), Proteostasis Therapeutics (PTI), Geron (GERN), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO) and Anavex Life Sciences (AVXL). This page (NASDAQ:IDRA) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Idera Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.